Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab
Flora Elwes, Shyamanga Borooah*, Peter Aspinall, Peng Yong Sim, Cheng Yi Loo, Ana-Maria Armbrecht, Baljean Dhillon, Peter Cackett
Dive into the research topics of 'Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab'. Together they form a unique fingerprint.